Quick Answer
Nuvation Bio Inc. reported Stockholders Equity of $305.72 million for the year ending 2025.
- Nuvation Bio Inc. showed a decrease of -34.1% in Stockholders Equity from 2024 to 2025.
- This data is from Nuvation Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $110.16 million | Q2 2020: $102.88 million | Q3 2020: $91.85 million | Q1 2021: $806.34 million | Q2 2021: $788.94 million | Q3 2021: $769.37 million | Q1 2022: $723.56 million | Q2 2022: $693.08 million | Q3 2022: $667.94 million | Q1 2023: $641.07 million | Q2 2023: $624.63 million | Q3 2023: $611.59 million | Q1 2024: $594.04 million | Q2 2024: $257.19 million | Q3 2024: $502.71 million | Q1 2025: $419.46 million | Q2 2025: $372.91 million | Q3 2025: $325.88 million.
- Over the full 8 years of available data (2019 to 2025), Nuvation Bio Inc.'s Stockholders Equity has grown by 159.6%.
- Historical annual values: Fiscal year 2025: $305.72 million | Fiscal year 2024: $463.79 million | Fiscal year 2023: $605.12 million | Fiscal year 2022: $655.08 million | Fiscal year 2021: $746.00 million | Fiscal year 2020: $215.08 million | Fiscal year 2020: $0.00 | Fiscal year 2019: $117.75 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: